Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine, ...
Food and Drug Administration commissioner Martin Markary speaks during an event in the Roosevelt Room at the White House, Monday, May 12, 2025, in Washington. (AP Photo/Mark Schiefelbein) WASHINGTON ...
The U.S. Food and Drug Administration on Friday authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by the end of next ...
FILE - A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George's University hospital in London, Oct. 7, 2020. (AP Photo/Alastair ...
FDA widens its Covid vaccine safety review as HHS Secretary Robert F. Kennedy Jr. questions longstanding guidance and companies defend their records.